An observational, prospective, single-center study evaluating safety and efficacy of pharmacological cardioversion of Flecainide, Ibutilide, Vernakalant and Amiodarone in patients with recent-onset atrial fibrillation.
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Amiodarone (Primary) ; Flecainide (Primary) ; Ibutilide (Primary) ; Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; Therapeutic Use
- 20 Jun 2016 New trial record
- 11 May 2016 Endpoint has not been met (Successful pharmacological conversion of recent-onset atrial fibrillation (AF) to restoring sinus rhythm), as per an article published in the American Journal of Emergency Medicine
- 11 May 2016 Results published in the American Journal of Emergency Medicine